NCT03695705View on ClinicalTrials.gov

Rifaximin and Norfloxacin for Prevention of SBP in Adults With Decompensated Cirrhosis

PHASE3CompletedINTERVENTIONAL
Enrollment

142

Participants

Timeline

Start Date

January 1, 2016

Primary Completion Date

December 31, 2016

Study Completion Date

June 30, 2017

Conditions
Cirrhosis, Liver
Interventions
DRUG

Rifaximin 550 mg twice a day and Norfloxacin 400 mg once a day

Patients on Rifaximin prophylaxis will be given 550 mg twice daily and on Norfloxacin prophylaxis will receive Norfloxacin 400 mg once daily for 6 months

All Listed Sponsors
lead

Post Graduate Institute of Medical Education and Research, Chandigarh

OTHER

NCT03695705 - Rifaximin and Norfloxacin for Prevention of SBP in Adults With Decompensated Cirrhosis | Biotech Hunter | Biotech Hunter